TBPH – theravance biopharma, inc. - ordinary shares (US:NASDAQ)
Stock Stats
News
Theravance Biopharma to Participate in an Upcoming Investor Conference
Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer [Yahoo! Finance]
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? [Yahoo! Finance]
Theravance Biopharma, Inc. (NASDAQ: TBPH) is now covered by analysts at BTIG Research. They set a "buy" rating and a $21.00 price target on the stock.
Form 8-K Theravance Biopharma, For: May 08
Form SC 13G/A Theravance Biopharma, Filed by: Madison Avenue Partners, LP
Form 4 Theravance Biopharma, For: May 01 Filed by: Samaha Eli
Form DEF 14A Theravance Biopharma, For: May 08
Form 4 Theravance Biopharma, For: Apr 02 Filed by: Winningham Rick E
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.